@FiercePharma: Top-read news in FP Thurs: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. Article | Follow @FiercePharma
@TracyStaton: ICYMI this week: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton
@EricPFierce: DEA tightens prescribing, limits refills on opioid combo pills like #Vicodin. Story | Follow @EricPFierce
@CarlyHFierce: ICYMI earlier - Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. Article | Follow @CarlyHFierce
> Eli Lilly ($LLY) has been accused in Brazil of filing unnecessary lititgation to try to hold off generic competition to a drug. Report
> The European Medicines Agency has agreed to review Cubist Pharmaceuticals' ($CBST) investigational antibiotic ceftolozane/tazobactam for urinary tract and abdominal infections. Release
> Mylan ($MYL) has launched a generic version of Upsher-Smith's Klor-Con for low potassium. Release
> A study from the Canadian Health Policy Institute says that the longer time that Canada takes to approve drugs, compared to the EU, has not resulted in a fewer risks for residents. Report
Medical Device News
@FierceMedDev: Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. ICYMI yesterday | Follow @FierceMedDev
@VarunSaxena2: UPDATED with table of deadlines: FDA clarifies UDI requirements with new guidance. Story | Follow @VarunSaxena2
@EmilyWFierce: Pruning of synapses in brain could provide clues to how autism develops in children, say scientists. More from the NYT | Follow @EmilyWFierce
> Google Ventures, Kleiner Perkins back enterprise wearables startup. More
> FDA clears AliveCor smartphone plug-in heart monitor to detect atrial fibrillation. Article
> Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. Story
Biotech News
@FierceBiotech: Low levels of enzyme in Alzheimer's brains suggest new drug target. More from FierceBiotech Research | Follow @FierceBiotech
@JohnCFierce: ICYMI yesterday: J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test. Report | Follow @JohnCFierce
@DamianFierce: A glimpse at the glamorous hedonism that runs rampant in Big Pharma. Image | Follow @DamianFierce
@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce
> Pfizer-AstraZeneca sequel could hit theaters next week. Article
> Cubist nears another big antibiotic approval as M&A rumors simmer. Story
> Israel's NeuroDerm banks $16M to advance its Parkinson's pump. More
And Finally... Speculation about why Amazon ($AMZN) officials met with the FDA ranges from the retailer wanting to sell FDA regulated products online to doing something itself in the mobile healthcare arena. Story